Calling all Clinical Phase I Outsourcing Professionals!

Posted:
4
February 2007

Do You Outsource Phase I Clinical Trials?Outsourcing remains a critical aspect of clinical development. All major drug development projects rely on one or more partners to aid the drug development process. The 9th Annual Phase I Clinical Trials conference on 19-20 February at Olympia Conference Centre, London will highlight the following:

  • A timely update on the guidance for first man studies � the revision of EMEA guidelines
  • What are the challenges and priorities over the next five years for the MHRA
  • How to manage potentially 'high risk' complex molecules. Tegenero: a case study
  • The challenges of conducting phase I studies in patients

Get the answers you need to all your outsourcing questions and meet the team from Richmond Pharmacology, the Early Phase CRO that can help you achieve your goals.Wednesday 20 February 2008 at 2pm, Dr. Jörg Täubel MFPM, MD, Managing Director, Richmond Pharmacology, invites you to discuss "Why carry out Phase 1 Trials in the UK, focussing primarily on the regulatory implications of conducting Phase 1 studies in the UK".We look forward to meeting you at the Congress. Visit the Richmond Pharmacology team at Stand No 3 to discuss your Early Phase outsourcing requirements.Exhibitor DiscountAs exhibitors we are delighted to offer you a discount of 25% off the first person and 15% off each additional person after that if you would like to attend the conference. Please call Angela Davie, Business Development Manager, on 020 8664 5200 or book direct quoting our VIP CODE - TT30 and booking code TT30Spex.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more